Global - Joint AAHFN/HFSA: Multidisciplinary Strategies for Managing Patients with Worsening Heart Failure with Reduced Ejection Fraction

Select a ModuleModule DetailsReview MaterialsEvaluate ModulePrint Certificate

Worsening heart failure (WHF), characterized by development of progressively escalating symptoms and signs of HF requiring intravenous diuretic treatment in the outpatient, emergency department, or hospitalized setting, is associated with a poor prognosis. This session will provide a review of the benefits of the multidisciplinary team to identifying and treating worsening heart failure, including the strategies and benefits of ambulatory intravenous diuretic administration and review of the roles for new and emerging therapies for HFrEF. 


Robert Page, PharmD
John Teerlink, MD
Sara Paul, DNP, FNP

Learning Outcomes:

  • Differentiate worsening heart failure from acute heart failure
  • Discuss the role and indications for administration of GDMT and intravenous diuretics in the community as strategy to reduce emergency department visit or hospitalization
  • Describe the characteristics and outcomes of patients with HFrEF and worsening heart failure
  • Recall treatment options and emerging therapies available for patients with recent worsening heart failure
  • Using a case study, identify potential roles for new and emerging therapies in a more personalized treatment of patients with HFrEF

Accreditation Statement
This activity is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

Disclosure/Conflicts of Interest
The planners and faculty for this activity do not have any relevant relationships to disclose unless listed below. Any resulting conflicts of interest have been resolved according to ANCC guidance.

Sara Paul, DNP, FNP:  Abbott; GUIDE-HF Steering Committee

John Teerlink, MD:  Consulting Fee:  3ive Labs, Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis, Verily, ViCardia, Windtree Therapeutics

Contracted Research: Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardurion, Cytokinetics, Medtronic, Novartis, ViCardia, Windtree Therapeutics

Disclosure of Commercial Support
This activity is supported by an independent educational grant from Cytokinetics Incorporated.  

Enduring Education Activity
Expiration Date: December 31, 2022
1.0 Contact Hours ANCC